english.prescrire.org > Spotlight > "Spotlight" > Biosimilar drugs: consultation on streamlining their development and evaluation

"Spotlight"

Biosimilar drugs: consultation on streamlining their development and evaluation

 Advancing Healthcare Policy  In September 2025, Prescrire responded to a consultation by the European Medicines Agency (EMA) on its requirements in relation to the development and evaluation of biosimilars.
Full article available for download (FREE)

 ©Prescrire 1 July 2026

Source: "Biosimilar drugs: consultation on streamlining their development and evaluation" Prescrire Int 2026; 35 (283): 195. FREE.

Filet

Enjoy full access to Prescrire International, and support independent information